✦ LIBER ✦

Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II Study

✍ Scribed by Alfredo Falcone; Elisabetta Pfanner; Claudia Cianci; Romano Danesi; Isa Brunetti; Mario Del Tacca; Pier Franco Conte

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 358 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950115)75:2<440::aid-cncr2820750205>3.0.co;2-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of paclitaxel in patients

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

✍ Edgardo Rivera; Frankie A. Holmes; Debra Frye; Vicente Valero; Richard L. Theria 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

Alternating chemotherapy regimens for pa

Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics

✍ David T. Kiang; B. J. Kennedy; Jerry Younger; Michael C. Perry; Albert Schilling 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 476 KB 👁 1 views

Background. Chemotherapy is most effective when applied during the biologically active stage of tumor cells. According to the authors' previous tumor marker kinetic study, methotrexate plus 5-fluorouracil (MF) was found to yield either a cytolytic effect in an MF-sensitive tumor cell population or a

A north central cancer treatment group P

A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma

✍ Henry C. Pitot; James A. Knost; Michelle R. Mahoney; John Kugler; James E. Krook 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

A phase II study of piritrexim in patien

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

✍ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the